linkedin post 2013-02-10 06:31:00

Uncategorized
MIXING DISCIPLINES CAN BE A GIANT LEAP FORWARD, as suggested in this use of supercomputing in medical decision-making, where accuracy in lung cancer treatment choices apparently jumps significantly with the computer. But remember Hitch Hiker's Guide: you are only as good as the question you ask. Put another way, the programming team are the potential weak link. http://lnkd.in/Zu6QTm View in LinkedIn
Read More

linkedin post 2013-02-10 06:12:22

Uncategorized
THERE ARE DIFFERENT RULES FOR DIFFERENT SPACES IN ENTREPRENEURING and when the rules become generalized they become less true or even useless. Social media is different from Biopharma. In Biopharma there is no "launch early" and most "disruptive" plays have been made decades ago. Make sure you don't get confused by great advice from an unrelated sector. http://lnkd.in/pkcuyK View in LinkedIn
Read More

linkedin post 2013-02-09 07:04:53

Uncategorized
TO BETTER UNDERSTAND A BIOTECH VC PERSPECTIVE, READ THIS very thoughtful summary of lessons and observations by a VC. If you understand their perspective better, you may reduce your risk of a misunderstood relationship. Understand clearly that VCs are also trying to figure out investing in early stage tech companies, and are themselves evolving all the time. The candid section about disastrous syndicates being a wrecking ball for portfolios is a good example. http://lnkd.in/T6UeW4 View in LinkedIn
Read More

linkedin post 2013-02-09 06:45:51

Uncategorized
WE ARE ONLY LIMITED BY OUR IMAGINATIONS. This beautifully bold work by scientists shows that the bubble can be pushed very far today. We are not far off an era where test-tube organs, and now hips, are something that we can hope for within our lifetimes. Stunning. http://lnkd.in/EYBtm3 View in LinkedIn
Read More

linkedin post 2013-02-09 06:39:29

Uncategorized
READ THIS GOOD REVIEW OF BIOTECH IPOs SINCE 2000. Liquidity drives VC investments. There are two main liquidity paths: IPOs, and M&A. Without liquidity events, investors cannot get their ROI. Unfortunately the IPO exit has been miserable for biotech, and the slack has not been taken up substantially by acquisitions. " "While these trends tend to be cyclic, the current downturn has a very chilling effect on investments. http://lnkd.in/tvw_Kb View in LinkedIn
Read More

linkedin post 2013-02-08 05:53:02

Uncategorized
LANGUAGE AFFECTS THINKING in numerous ways. Redefining words, as this author persuasively suggests, can profoundly change attitudes. She suggests redefining the word RISK. An excellent start. Another to consider in Europe and Japan is AMBITION, which carries negative baggage in both geographies. A worthy experiment! http://lnkd.in/9gmJZh View in LinkedIn
Read More

linkedin post 2013-02-08 05:45:06

Uncategorized
ANALYSTS HAVE TRADITIONALLY DISLIKED BRAND-GENERIC COMBINATION COMPANIES, but there are many reasons to challenge this prevailing false assumption. Bolting on a revenue stream that is not as difficult to achieve as a new brand drug gives a company operating and R&D revenues. Impax Labs has successfully funded its R&D efforts from sales of generics, and without that capital source would have needed to finance R&D externally. Rethink sustainable business models. http://lnkd.in/D-5Ye6 View in LinkedIn
Read More